Herceptin (trastuzumab)

P2, N=48, Active, not recruiting, Carey Anders, M.D. | Trial primary completion date: Apr 2026 --> Nov 2026 | Trial completion date: Jul 2026 --> Nov 2027

P2, N=52, Recruiting, University of Wisconsin, Madison | Trial completion date: Dec 2027 --> May 2028 | Trial primary completion date: Dec 2026 --> Dec 2027

P1/2, N=380, Recruiting, BioNTech SE | Trial completion date: May 2029 --> Aug 2029 | Trial primary completion date: May 2028 --> Aug 2029

We present the case of a 60-year-old non-smoking woman previously treated for luminal B human epidermal growth factor receptor 2 (HER2)-positive invasive breast carcinoma with surgery, AC60 chemotherapy, trastuzumab, breast radiotherapy, and hormone therapy at the Mohammed VI Oncology Center in Casablanca, Morocco. The patient received neoadjuvant vinorelbine-cisplatin chemotherapy followed by volumetric modulated arc therapy (VMAT) thoracic radiotherapy at 66 Gy, achieving clinical and radiological stabilization. This case highlights the occurrence of a second driver-negative primary lung adenocarcinoma in a non-smoker and underscores the importance of integrated histopathological, immunohisto chemical, and targeted molecular evaluation in distinguishing primary tumors from metastases, as well as the potential role of post-therapeutic carcinogenesis.

P1, N=27, Active, not recruiting, Institut Paoli-Calmettes | Recruiting --> Active, not recruiting

In this Romanian single-center cohort, pCR was independently predicted by clinical subtype and a limited set of biological variables, in line with contemporary literature. Although baseline patient-reported outcomes did not improve prediction of pathological response, the high prevalence of pre-treatment anxiety and the emergence of clinical depression during NAC argue for systematic psychosocial screening as part of standard neoadjuvant care.

Data suggest that the Fab-ageritin IT and the individual purified components preserve the toxin and Fab' activity but show enhanced cell toxicity, thus resulting in a structurally well-defined, target-specific new type of immunotoxin. The scheme outlined for its preparation is easily extendable to other therapeutic IgG1 thus providing a significant contribution to the ongoing effort to explore new combinations of payloads and targeting platforms for next-generation immunotoxins.

Neoadjuvant dual HER2 blockade with trastuzumab and pertuzumab plus chemotherapy represents the current standard-of-care for HER2-positive breast cancer. Importantly, Xenium in situ profiling further revealed biological correlates underlying model predictions, including HER2-enriched tumor cell aggregation and neutrophil-helper T-cell interactions, thereby highlighting the mechanistic interpretability of the model. Collectively, HER2-LADDER unites digital pathology and high-resolution spatial profiling into a clinically accessible AI framework, offering a robust, transparent, and biologically grounded tool to tailor individualized HER2-targeted therapy optimization.

P1, N=28, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended | Trial primary completion date: Apr 2026 --> Aug 2026

In a multivariate regression analysis the cumulative dose of anthracycline (OR = 1.01, 95% CI: 1.00-1.01, p = 0.002) and LVEF at baseline (OR = 0.83, 95% CI: 0.70-0.99, p = 0.0344) were independent predictors of a cardiotoxic effect. Trastuzumab-related cardiotoxicity resulting in early treatment discontinuation negatively influences DFS, but does not seem to influence OS.

P2, N=63, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

P2, N=124, Recruiting, The First Affiliated Hospital of Soochow University